- Home
- AKBA vs SABA Comparison
AKBA vs SABA Comparison
Compare AKBA & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AKBA | SABA |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | United States |
| Employees | 194 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 221.3M |
| IPO Year | 2014 | 1994 |
Fundamental Metrics
Financial Performance| Metric | AKBA | SABA |
|---|---|---|
| Price | $0.89 | $8.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.67 | N/A |
| AVG Volume (30 Days) | ★ 6.3M | 55.0K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | ★ 93.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $7.80 |
| 52 Week High | $3.19 | $9.18 |
Technical Indicators
Market Signals| Indicator | AKBA | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 40.09 |
| Support Level | $0.85 | $7.97 |
| Resistance Level | $0.98 | $8.40 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 1.40 | 32.12 |
Price Performance
Historical ComparisonAbout AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.